{"pmid":32439211,"title":"Immune checkpoint inhibitors in SARS-CoV-2 infected cancer patients: the spark that ignites the fire?","text":["Immune checkpoint inhibitors in SARS-CoV-2 infected cancer patients: the spark that ignites the fire?","Lung Cancer","Di Noia, Vincenzo","D'Aveni, Alessandro","Squadroni, Michela","Beretta, Giordano Domenico","Ceresoli, Giovanni Luca","32439211"],"journal":"Lung Cancer","authors":["Di Noia, Vincenzo","D'Aveni, Alessandro","Squadroni, Michela","Beretta, Giordano Domenico","Ceresoli, Giovanni Luca"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32439211","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.lungcan.2020.05.006","topics":["Case Report"],"weight":1,"_version_":1667523504783753216,"score":9.490897,"similar":[{"pmid":32290754,"pmcid":"PMC7161588","title":"Do checkpoint inhibitors compromise the cancer patients' immunity and increase the vulnerability to COVID-19 infection?","text":["Do checkpoint inhibitors compromise the cancer patients' immunity and increase the vulnerability to COVID-19 infection?","The severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) has been declared a pandemic by the WHO that claimed the lives of thousands of people within a few months. Cancer patients represent a vulnerable population due to the acquired immunodeficiency associated with anti-cancer therapy. Immune checkpoint inhibitors have largely impacted the prognosis of a multitude of malignancies with significant improvement in survival outcomes and a different, tolerable toxicity profile. In this paper, we assess the safety of ICI administration in cancer patients during the coronavirus pandemic in order to guide the usage of these highly efficacious agents.","Immunotherapy","Kattan, Joseph","Kattan, Clarisse","Assi, Tarek","32290754"],"abstract":["The severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) has been declared a pandemic by the WHO that claimed the lives of thousands of people within a few months. Cancer patients represent a vulnerable population due to the acquired immunodeficiency associated with anti-cancer therapy. Immune checkpoint inhibitors have largely impacted the prognosis of a multitude of malignancies with significant improvement in survival outcomes and a different, tolerable toxicity profile. In this paper, we assess the safety of ICI administration in cancer patients during the coronavirus pandemic in order to guide the usage of these highly efficacious agents."],"journal":"Immunotherapy","authors":["Kattan, Joseph","Kattan, Clarisse","Assi, Tarek"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32290754","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.2217/imt-2020-0077","keywords":["covid-19","cancer","checkpoints inhibitors","coronavirus","immune therapy","immunosuppression"],"topics":["Treatment"],"weight":1,"_version_":1666138494474387457,"score":48.831593},{"pmid":32388171,"title":"SARS-COV-2 infection in patients with cancer undergoing checkpoint blockade: Clinical course and outcome.","text":["SARS-COV-2 infection in patients with cancer undergoing checkpoint blockade: Clinical course and outcome.","Eur J Cancer","Di Giacomo, Anna M","Gambale, Elisabetta","Monterisi, Santa","Valente, Monica","Maio, Michele","32388171"],"journal":"Eur J Cancer","authors":["Di Giacomo, Anna M","Gambale, Elisabetta","Monterisi, Santa","Valente, Monica","Maio, Michele"],"date":"2020-05-11T11:00:00Z","year":2020,"_id":"32388171","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.ejca.2020.04.026","topics":["Case Report"],"weight":1,"_version_":1666428892731146240,"score":48.15703},{"pmid":32434790,"title":"COVID-19 and immune checkpoint inhibitors: initial considerations.","text":["COVID-19 and immune checkpoint inhibitors: initial considerations.","COVID-19 infections are characterized by inflammation of the lungs and other organs that ranges from mild and asymptomatic to fulminant and fatal. Patients who are immunocompromised and those with cardiopulmonary comorbidities appear to be particularly afflicted by this illness. During pandemic conditions, many aspects of cancer care have been impacted. One important clinical question is how to manage patients who need anticancer therapy, including immune checkpoint inhibitors (ICIs) during these conditions. Herein, we consider diagnostic and therapeutic implications of using ICI during this unprecedented period of COVID-19 infections. In particular, we consider the impact of ICI on COVID-19 severity, decisions surrounding continuing or interrupting therapy, diagnostic measures in patients with symptoms or manifestations potentially consistent with either COVID-19 or ICI toxicity, and resumption of therapy in infected patients. While more robust data are needed to guide clinicians on management of patients with cancer who may be affected by COVID-19, we hope this commentary provides useful insights for the clinical community.","J Immunother Cancer","Sullivan, Ryan J","Johnson, Douglas B","Rini, Brian I","Neilan, Tomas G","Lovly, Christine M","Moslehi, Javid J","Reynolds, Kerry L","32434790"],"abstract":["COVID-19 infections are characterized by inflammation of the lungs and other organs that ranges from mild and asymptomatic to fulminant and fatal. Patients who are immunocompromised and those with cardiopulmonary comorbidities appear to be particularly afflicted by this illness. During pandemic conditions, many aspects of cancer care have been impacted. One important clinical question is how to manage patients who need anticancer therapy, including immune checkpoint inhibitors (ICIs) during these conditions. Herein, we consider diagnostic and therapeutic implications of using ICI during this unprecedented period of COVID-19 infections. In particular, we consider the impact of ICI on COVID-19 severity, decisions surrounding continuing or interrupting therapy, diagnostic measures in patients with symptoms or manifestations potentially consistent with either COVID-19 or ICI toxicity, and resumption of therapy in infected patients. While more robust data are needed to guide clinicians on management of patients with cancer who may be affected by COVID-19, we hope this commentary provides useful insights for the clinical community."],"journal":"J Immunother Cancer","authors":["Sullivan, Ryan J","Johnson, Douglas B","Rini, Brian I","Neilan, Tomas G","Lovly, Christine M","Moslehi, Javid J","Reynolds, Kerry L"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32434790","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1136/jitc-2020-000933","keywords":["cytotoxicity, immunological"],"topics":["Treatment"],"weight":1,"_version_":1667521393781112833,"score":47.348812},{"pmid":32212881,"pmcid":"PMC7117596","title":"Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors.","text":["Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors.","Immunotherapy","Bersanelli, Melissa","32212881"],"journal":"Immunotherapy","authors":["Bersanelli, Melissa"],"date":"2020-03-28T11:00:00Z","year":2020,"_id":"32212881","source":"PubMed","week":"202013|Mar 23 - Mar 29","doi":"10.2217/imt-2020-0067","keywords":[" anti-ctla-4","covid-19","sars-cov-2","anti-pd-1","anti-pd-l1","cancer patients","immune checkpoint inhibitors","immunotherapy","tocilizumab","viral infection"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138490525450240,"score":44.9101},{"pmid":32489118,"title":"Risk of SARS-CoV-2 infection and disease in metastatic triple-negative breast cancer patients treated with immune checkpoint inhibitors.","text":["Risk of SARS-CoV-2 infection and disease in metastatic triple-negative breast cancer patients treated with immune checkpoint inhibitors.","Immunotherapy","Vici, Patrizia","Pizzuti, Laura","Krasniqi, Eriseld","Botticelli, Andrea","Ciliberto, Gennaro","Barba, Maddalena","32489118"],"journal":"Immunotherapy","authors":["Vici, Patrizia","Pizzuti, Laura","Krasniqi, Eriseld","Botticelli, Andrea","Ciliberto, Gennaro","Barba, Maddalena"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32489118","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.2217/imt-2020-0142","keywords":["covid-19","immunotherapy","metastatic triple-negative breast cancer"],"topics":["Prevention"],"weight":1,"_version_":1668623433729048577,"score":43.47054}]}